Moderna CEO Stéphane Bancel received an annual compensation package worth $19.87 million last year, the largest he’s ever ...

Companies including CureVac, Afrigen Biologics, Moderna ... So far, however, no mRNA vaccine has been approved for clinical use against a bacterial target. Afrigen and Evaxion began working ...

Now that Novavax has been added to the revamped COVID vaccines, you'll want to make sure to check on the changes to cost and ...

The COVID-19 vaccine maker reported quarterly sales ... from Overweight to Equal-Weight and lowers the price target from $111 to $45. Moderna Stock Prediction For 2025 Equity research can be ...

BofA analyst Tim Anderson lowered the firm’s price target on Moderna (MRNA ... the combo flu+COVID program will require Moderna to demonstrate vaccine efficacy of the stand-alone flu component ...

Moderna’s Q4 2024 earnings call highlighted its ongoing challenges in the respiratory vaccine market and its ... while cost reductions and a cash cost target of $5.5 billion in 2025 demonstrate ...

A trial of Moderna’s norovirus vaccine in the U.S. has been put on hold by the FDA over a reported case of neurological disorder. The phase 3 study is evaluating the candidate, dubbed mRNA-1403 ...

“The companies told the PTAB in the petitions that Moderna’s patents include ‘unimaginably broad claims directed to a basic idea.’” Patent Trial and Appeal Board (PTAB) docket entries ...

with a breakeven target in 2028. Operating expenses are projected to decrease significantly from $9 billion in 2023 to $5 billion by 2026. Moderna paused its norovirus vaccine study but expects no ...

The prefusion conformation of the F protein is a significant target of potent neutralizing antibodies and is highly conserved across both RSV-A and RSV-B subtypes. To date, Moderna has received ...